everyone. New A Chuck great you, day York. morning Thank in good and here
the access performance, on are speak sustained affordable growth, our innovative provide discuss will we third and vaccines. of touch and the battle for briefly period to in to it anticipated our how setting pipeline against on progress the update is us COVID-XX, an I business and quarter of an making topic remarks, my up medicines During strong
Biopharmaceutical update Let's Group. on an our start with
an of grew business XTANDI. quarters, COVID-XX. of by Year-to-date brands business of in by includes performance impact continued our growth ongoing biopharma million For strong Vyndaqel/Vyndamax; quarter, grew to X% three and and biopharma X% of or including Xeljanz, the portfolio unfavorable primarily strength operationally impact the Inlyta, These revenues biosimilars; to through leading include million approximately an or the X% driven IBRANCE, our Eliquis, key the COVID-XX. operationally of revenues due unfavorable results estimated X% approximately $XXX estimated due which $XXX from
approximately revenues global to strong to continues operationally operational X% was to IBRANCE Oncology in quarter cancer. the the revenues class year quarter. the In metastatic increased for particularly XX% inhibitor up $X.X compared Global quarter. leader in IBRANCE the the breast X% CDKX/X business and billion IBRANCE Our ago a in grew be U.S.,
price which through U.S. the and agreements of where in last markets operational expect U.S. in volume EU quarter CDKX/X certain growth XX the resulted the benefit eight price revenue In impact we in reductions The markets of fact price by the growth inhibitor annualized. will were as clinical the growth renegotiation XXXX the more long-term it a IBRANCE. than change patients quarter. volume prescribed reductions a delivered offset to patients These as outside well The The international the overall the received profile. as testament of should was continued as continue delivers its to of fourth X% serve result robust year in occurred to out XX% is who a
from approved This performance by for the breast the evidence trials over of expected and physician PALLAS disappointed driven of by of body PENELOPE-B confidence we and IBRANCE HR+ and strong by experience. by two metastatic positioning breast clinical combination the as patient metastatic clinical outcomes evidence positive new well treatment In is supported extensive data, of an using five for confident continued analysis, HERX-negative including cancer. real-world as in were therapies, practice, currently remain years everyday cancer, we data. strong While IBRANCE's is future
alliance the X by during U.S. on quarter future by indicator XTANDI FDA renal million XX% Inlyta million. continued cell Inlyta strong which of combination increase advanced patient XX% leading driven revenues quarter. were continues up approvals U.S. Inlyta of performance our royalty following was operationally In the U.S., approved prostate was in $XXX also metastatic and be tends totaled treatment metastatic combined in in markets when indications. all checkpoint year's with with to sales growth. in in the and uptake new for performance utilization Inlyta inhibitors ex-U.S. in the with For the Growth the non-metastatic income very indications, to across the carcinoma. a first-line the of $XXX XTANDI patients lead driven good performance. a Global XX% revenues cancer increased with to starts castration-sensitive immune for international castration-resistance to operational contributed The for and last
to as U.S. alliance expansion has growth increased Now sales Pfizer's price as the of strong turning offset including volume an of to deliver categories. the revenues other net our due certain key very channel XX% gap VYNDAQEL continued coverage was direct products In performance. quarter. the U.S., in number gap markets up and Medicare in to was share by that third their and $X.X performance. continued unfavorable operationally VYNDAMAX strong of well therapeutic to the partially X% from mix. Eliquis strong billion lives lower the global a
end in XX,XXX patients than XX,XXX X% more to to Our quarter the received drug. disease X% launch. awareness At more prior been more and than more a have X,XXX efforts quarter of patients the have been compared received helped and diagnosis to the the drive diagnosed XX% the than patients have prescription estimated rate only with than
the the stay-at-home orders drug that had out in began operational was QX I expected patient $XXX monitor. receiving of patients also are and at in the the revenues grew operationally the from QX, compared in and in were to in approximately average international see our that primarily growth third slowdown of quarter X,XXX. XX% the programs. taking saw underlying XX% will patients the cost XXXX. Xeljanz we new in estimate due up we and U.S. continue the XX% driven include will to numbers through we no markets. a rebound quarter, quarter point For in who diagnosis Global U.S. These to number demand million, prescription by in assistance we the growth to X% developed The U.S. with VYNDAQEL
in global XX% biosimilars has from driven enabling which by primarily $XXX operationally million. growth. our portfolio Revenues formulary which This volume our We access played to role in in generated grew have the U.S., invested biosimilars, a this was oncology revenue were international greater X% of billion. outside arising revenues the markets, to XX the Prevnar from Global adult million. from Revenues the uptake U.S. grew resulting pandemic. XX% in $XXX increased $X.X by down resume vaccine primarily certain operationally, of COVID-XX driven awareness vital
Although is at XX revenues reflecting individual prevention meaning compared of of adult with from shared year made well the we and between the resulting decision-making down a SARS-CoV-X should for their ordering pneumonia level care should Prevnar timing be primarily impact pneumococcal XX%, health patterns government decision and recommendation, the U.S., providers vaccinate to last pediatric China. as clinical were not indicated patients. that note In as bacteria of uptake strong the the in continued
a recovery quarter. by from misdoses was All of offset this the of partially of portion second
competition, to anticipated: a had revenues primarily billion of that XX% the factors implemented the volume-based in down nationwide we The program, $X.X in X China, to multisource the that significant was Upjohn. in expected of in words March XXXX; XXXX. driven July was XXXX; about lower which began declines competition June Now decline Japan from Lyrica in initially resulting few for began Lipitor Norvasc and Upjohn in lower due generic Celebrex XXXX by quarter, for and volume revenues of for which December and due impact totaled U.S. the in volume that procurement in operationally. expanded the was generic
this the to We expect the with occur transaction continue of Mylan closing quarter. to Upjohn
allowed XX,XXX and planned than beginning we participants update developing is as at with Now, second stable their of United with the including our more Africa Brazil, nearly including in States, our enrollment include XX,XXX trial an our our sites HIV, has study, people to populations them C, people enrolled young additional initial from old us the Turkey, hepatitis having chronic with Germany, received R&D XX,XXX Phase candidate people for B. and to date COVID-XX approximately our are hepatitis years This has as study XX partner XX,XXX We on related the people. study expanded to approximately BioNTech around I South turn in the X dose. ongoing mRNA world, vaccine The clinical efforts. XXX and To that will pipeline, global with our Argentina.
soon. from we conclusive analysis it the that not the any open today efficacy an been case today's interim of to whether call, within that as letter, estimate complete completed the will clear in to today. not or do I interim intend unblinded we week But administrative inform monitoring may demonstrates not reiterated soon have we necessary want conclusive to data be time we say publicly which the we data, nor efficacy speak efficacy after as know until I committee. In can we be monitoring to earnings negative, readout, about or conducted public we has analysis, data a As readout committee work, the positive the a vaccine we has know. one from
third safety half requiring participants, Based of early perfect use And in manufacturing a investing final up reach that dose build for is since an this vaccine, of effort at capacity. the November. week emergency our risk processes trial authorization has been current FDA the U.S. in our days potential and vaccine. in we on to dosing milestone of the we of rapidly two For estimate data the trial pace, the companies of and enrollment on finally, provide the Pfizer the following months COVID-XX will pandemic
for our is to submission reached. manufacturing safety ready expect have We the milestone before data
soon to is in for of safety in be positive will the November. we milestone assuming data, after Pfizer So third which apply the expect achieved, use the week emergency authorization U.S.
study planning study XXXX. believe our inhibitor help candidate, approval we for the the treat half antiviral patients. are of this second initiated XXXX Xb a hopes early September meaningful antiviral to in Phase late a and Regarding Phase demonstrate to we activity the start opportunity with first-in-class of protease give XXXX X/X may pivotal in potential We in submitting COVID-XX us
Now, from great let's some of of continues strengths. to one the rest look at which pipeline, Pfizer's highlights be the
XX of Investor Xb dosed high have we dose gene an boys with presented data Phase Since virtual our high XX Day event treated Duchenne product. boy Investor September, treated additional bringing from a our therapy muscular overall. the Day, at dystrophin our us to During and in total a dose we update at
Importantly were no events among regimen. modularity adverse observed regimen who serious immuno treated using were monitoring modified boys XX additional the and a
October on Xth, in our joint the is received following press the which SB-XXX, XX along participant track treatment Phase gene annual release to the designation for in from end the FDA hemophilia months, the our partner of study for to we announce October X through year. we on this On have Sangamo Xst, participants patients. rate endpoint issued dosed is program. therapy first an clinical The primary Phase impact of X met investigational X, that A X AFFINE dosing with fast bleed X lead-in October study compared study events a OPKO treatment improved multicenter, We less begin before press the Additionally with this plan to with factor Phase III, its quarter. our of announcing dosed in biologics primary period. than study injection GENOTROPIN therapy our randomized, endpoint to VIII once-daily. were years Phase application hormone reported. plan the for partner burden issued that of release with to age once-weekly evaluating serious license adverse On administered replenishment crossover We open-label, deficiency, in with somatrogon XX our No we children compared file collected FDA a growth we
programs deep of on breast inhibitor cancer. leadership IBRANCE built CDK next-generation metastatic our and our Our knowledge
potential preclinically sold neutropenia the seen without treatments than target safe the improved IBRANCE been breast index combination CDKX and XX with more provide CDKX more potency therapeutic may cancer of to in types. CDKX inhibition. Our and has selective for inhibitor times opportunity other This with sometimes
tumors, started for with variety studies care HR+ in results, to IBRANCE efficacy including both. Because in these strong preclinical combination in programs two therapies. has especially, has CDKX the combine preclinical prevent Our a overcome potential of in to models of dosing we been and for to resistance inhibitor activation, CDKX these of selective or standard Phase patients with breast have I cancer drive in sold
patients. very antibody heavily signal multiple the of to data with pretreated Our a high projects. rate monoclonal and program BCMA/CDX clinical combination pivotal plan drug I strong multiple efficacy this myeloma a into bispecific generated response Phase study expand in supporting soon We clinical
Our and XXXX. up treatment of new drug the Abrocitinib for severe has old accepted XX for atopic moderate a years in by in FDA PDUFA with patients priority of application review dermatitis the April to age day been
Medicines authorization European has the marketing application. the Agency Additionally, for validated review
clinical trial itch statistically superior III as improvements skin has that and clearance, versus program Phase shown disease severity Abrocitinib demonstrated placebo. well improvements extent Our in in as
of vaccine X announced with recombinant fever and than demonstrated based results profile an tolerability VLAXX in Lyme serum II candidate observed rates and other the and sero-conversion with X tested. X group. study study adverse across of doses first Phase serious combinations. to important, matching second response X, greater immune VLAXX initial older no assay generally investigated The disease schedule dose bactericidal was be Most rates lipid-containing XX% this positive profile all had were against including its displayed Lastly serum X, VLAXX. including our formulations the all vaccination or months the age Compared related encouraging comparable were months types. doses. study on treatment well-tolerated to groups for partner candidate of vaccines antibodies induced adults a X And the of which schedule the events and Valneva found vaccines were any in lipidated studied
Phase positive increasingly and vaccine study. final regimen feel Phase the define followed Phase an candidate eagerly II expected III about we II study two confident awaiting studies, Lyme these this to pivotal by Given event are dosing
the biopharma expected will and smaller, Pfizer following know you innovative Upjohn-Mylan company. the of As but a closing transaction, be focused
growth of that risk-adjusted the at from a we timeframe basis expect beyond next portfolio. our X% on revenue Upjohn continued wave five-year of CAGR the separation, Following a least and patent-protected
same and this antiviral grow I a provided projections We that these during from EPS we period you clear projection. five-year would that our to to Day, is expected growth impact vaccine adjusted during Investor path potential that any Our remind COVID approximately XX%. exclude programs. our believe
we pipeline only about five-year we projected by of fact, indicated expected need that achieve In to XXXX CAGR. X%, XX% revenue our the non-risk-adjusted
the we increase in one and very moderate of consensus. the dermatitis. the patients biggest zero-sum We Abrocitinib So game potential general believe safe a have difference to we we in near-term good compound where severe number margin with Abrocitinib JAKs the error. of that the to treated of see biologics is this compared treatment a serving see and is not with atopic
are the financial functions and review from realized related these to and we being in actions begin XXXX. actions we our anticipated finalizing enabling benefits expect Lastly, --
I Before a I few want affordability. close, words to about say
medicines people said do our have breakthrough vaccines them. anyone good the we As if any in past, affordably and access won't can't
better patient patients, ensuring to ready the instead of to aligning by needs, like the cap both with patients. at middlemen. play aim table a role we an the Medicare policies debate the to D to that on what November, of prioritizing take will Regardless parties kept happens benefit constructive a passed at being in seat in That for design create committed in insurance Part out-of-pocket the shaping be working take are put of reforming are to and means rebates We patients that first. Washington with and
will I to turn Now, over it Frank.
